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The definitive champion of the 92nd Academy Awards, best 
known as the 2020 Oscar’s was the Korean film 기생충; 
Gisaengchung, translated to English as Parasite, directed by 
Bong Joon-ho, that premiered earlier, also with a win, at the 
2019 Cannes Film Festival (Figure 1). More good things are 
recently blooming from South Korea, including K-pop, the 
latest cell phones with ultra cameras, and last but not least, 
respiratory research.
In this issue of Annals of Translational Medicine, the 
group of Yang B, and colleagues (1), reported the burden 
associated with two common respiratory conditions, 
bronchiectasis and chronic obstructive pulmonary disease 
(COPD). They analyzed data from the Korea National 
Health and Nutrition Examination Survey (KNHANES), 
an annual survey conducted to investigate the health and 
nutrition levels of the Korean population aimed to establish 
and evaluate national health policies. KNHANES is a 
landmark study, that mirrors its US namesake, which is 
now running in its 14th iteration (2), and other nationally 
representative surveys elsewhere. KNHANES is embedded 
within their National Health Insurance system, which is 
compulsory and universal, and collects all medical claim 
data for all Koreans. Therefore, KNHANES is having 
a significant advantage for epidemiological research, 
previously observed in the Scandinavian environment only. 
Yang and colleagues (1), report that the frequency of 
self-reported diagnosis of bronchiectasis (0.8%) was ten 
times less common than spirometrically-confirmed COPD 
(12.6%), but the burden and costs associated with both were 
substantial, even though on average their bronchiectasis 
patients were five years younger than COPD patients. 
Interestingly, the observed increase with ageing seen in 
COPD prevalence by decade, that is of 4.2% in 40–49 yrs. 
old, 9.9% in 50–59 yrs. old, and 24.8% in those older than 
60 yrs. was not observed in bronchiectasis, with 0.2%, 1.1% 
and 1.2% respectively. Indeed, a major limitation of this 
study is related with the universal underdiagnosis that we 
see in all chronic respiratory conditions, which is magnified 
in here by the absence of imaging to identify bronchiectasis, 
specially in a population with high rates of untreated chest 
infections and smoking. This problem is even of greater 
concern in men, with an estimated population prevalence 
of smoking in 2015 in South Korea of 35.5%, and even 
greater (38.5%) in North Korean men (3). The prevalence 
of bronchiectasis is very variable by country and region, not 
only attributable to demographic factors associated with 
the age- and sex-pyramid distribution of every population, 
as it is an age-related condition, or with variations in past 
infection, tuberculosis, and climate determinants, but likely 
due to local variations in incidence, all beyond diagnostic 
practices and health development. A recent literature review 
reported extraordinary heterogeneity in its worldwide 
distribution, ranging from 42 to 566 cases per 100,000 per 
year (4), greater in women and in the elderly, although 
most likely they are all underestimates. A high prevalence 
of bronchiectasis is reported in South Korea (4) and in one 
particular study of respiratory patients, 9% were deemed to 
have bronchiectasis, with a higher prevalence in females (5). 
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With all likelihood, the coexistence of airflow imitation 
compatible with COPD and bronchiectasis identified 
by high- or low-dose computer tomography in the same 
patient (Figure 2) is not testimonial. A report from Spain 
found a 57.6% prevalence of bronchiectasis in patients with 
moderate to severe COPD, and this was associated with 
greater severe airflow obstruction, isolation of a potentially 
pathogenic microorganism from sputum, and at least one 
hospital admission for exacerbations in the previous year (6). 
Very recently, a systematic review meta-analyzed six 
observational studies by pooling 881 COPD patients, and 
reported a mean prevalence of bronchiectasis in patients 
with COPD of 54.3%, ranging from 25.6% to 69% (7).
In South Korea in particular, as well as it is seen in other 
countries in Asia, Africa and South America, bronchiectasis 
affects mostly post-infection patients, and at a younger age 
than those seen in Europe (4) Further, non-compliance 
with vaccinations during childhood, poor tuberculosis 
control, toxic inhalants, substandard treatment of other 
respiratory infections in adulthood due to drug shortages, 
non-compliance and lack of access to health systems, likely 
causes a greater impact for bronchiectasis incidence.
The finding of a low socioeconomic status associated 
with both respiratory conditions highlights the unmet 
burden that vulnerable populations worldwide suffer in 
their lungs. In this study, three quarters of participants with 
bronchiectasis and two thirds of those with COPD had a 
low family income, compared with less than half in those in 
Figure 1 기생충; Gisaengchung (Parasite) 2019, film directed by Bong Joon-ho.
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the control group. Worldwide, respiratory disease is on the 
increase, in part due to aging and population growth (8); 
but they are becoming an even higher toll for the poor, who 
overall endure more exposure to active and passive smoking, 
live in more polluted areas, work with unsafe air and often 
with poor hygiene, and lack access to preventive actions 
than their more priviledged counterparts (9). Recently, the 
Global Alliance for Chronic Disease (GACD) called for 
further research on the burden of all respiratory conditions 
and their multimorbidity (10).
A comment on spirometry in the KNHANES framework 
is granted. We are not told about quality control, devices, 
and other standards. Indeed, having spirometry measured 
in the general population is better than not having it, and 
it is an accepted KNHANES limitation they used preBD 
spirometry only, which likely inflates somehow the observed 
frequency of airflow limitation. Further, given that the 
control group of participants without respiratory disease 
had only percent predicted FVC of 92.0% and FEV1 of 
93.3%, when they should be closer to 100%, and that they 
also report frequently respiratory symptoms linked with 
bronchitis (6.4% cough and 12.8% sputum), it is unknown 
how sensible are lung measurements. Au contraire, a plus of 
this study is expressing predicted values according to local 
reference equations (11), which is a recommendation from 
GOLD and should be copied/exported in other countries. 
Constructively, it might be considered in future iterations 
after this KNHANES wave 2007 to 2009, that they lobby 
to include postBD spirometry and imaging by low-dose 
computer tomography, the latter at the least in a subsample 
of participants.
Another interesting finding by Yang B, and colleagues (1), 
is on comorbidities: depression was two-fold increased in 
bronchiectasis than in COPD patients, although we must 
bear in mind it was again self-reported based on previous 
physician diagnosis, just like in all other comorbidities. 
The Global Alliance Against Chronic Respiratory Diseases 
(GARD) initiative recommends that anxiety and depression, 
among other conditions, should be actively explored 
in respiratory patients, due to their higher frequency, 
correlation with higher dyspnoea, and eventual treatment. 
The bronchiectasis bacteriome in the Asia-pacific region 
identifies predominance of P. aeruginosa and H. influenzae. 
It appears that South Korea has a different distribution 
of bacteria in bronchiectasis patients, with high non-
tuberculosis mycobacteria (44.5%), similar to that of the 
US and lower rates of P. aeruginosa (18.1%), and also had 
a significant prevalence of K. pneumoniae (12). To date, our 
current understanding of the virome and mycobiome in 
bronchiectasis in this world region is limited, beyond the 
exploratory search of viruses and fungi in a few studies there.
Although tobacco is indeed the most relevant causal 
factor for COPD development, it is not yet described as an 
etiological cause of bronchiectasis, although tobacco alters 
the mucociliary clearance system and this will favor more 
infections. Regrettably, respiratory and non-respiratory 
smoking-related disease remain a significant health risk in 
Korea and elsewhere, Wraping up, we can envisage that the 
only “parasite”, even a predator parasite, in bronchiectasis 
and COPD patients, either in Korea and elsewhere, is 
tobacco and all types of smoking, from cigarettes (13) to 
new forms of heat-not-burn technologies and vaping (3). 
They should be periodically monitored well within this 21st 
century to capture the changing landscape of risk factors for 
all chronic respiratory ailments (14). Eventually, and beyond 
«Parasite» we may claim: “The Oscar goes to…” anti-
tobacco advocates in their fight for a world with no tobacco 
and therefore with less respiratory disease.
Figure 2 Lung function (A) and CT-scan (B) of a patient with overlapping bronchiectasis and COPD. Male, 78 yr. old, height 156 cm, 
weight 84 kg, with a tobacco smoking exposure of 50 pack-yr.; Spirometry post-bronchodilator: FVC: 1,790 mL (68.5%); FEV1: 790 mL 
(40.2%); FEV1/FVC: 0.44; TLC: 5,300 mL (98.5%); RV: 3,320 mL (131.4%); RV/TLC: 62.6 (141%); CT scan: large, cylindrical 
bronchiectasis in both lower lobes, and areas of emphysema. 
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